Erythema multiforme vs. dress syndrome associated with the combined use of lamotrigine and cyclobenzaprine: A case report

Lindsay T Morgan Bicknell, Marsal Sanches, Dawnelle Schatte

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Lamotrigine is FDA-approved as a maintenance treatment of bipolar disorder, but its common off-label uses include bipolar depression and antidepressant augmentation in patients with major depressive disorder. Among other adverse effects, cutaneous reactions, particularly erythema multiforme, are cited as concerns during treatment with this medication. In order to minimize the risk of cutaneous side effect, efforts have been made to identify factors associated with a higher rate of lamotrigine-induced rash. We report here a case of Drug Reaction with Eosinophilia and Systemic Symptoms apparently precipitated by the associated use of lamotrigine and cyclobenzaprine.

Original languageEnglish (US)
Pages (from-to)305-314
Number of pages10
JournalInternational Journal of Psychiatry in Medicine
Volume44
Issue number4
DOIs
StatePublished - 2012
Externally publishedYes

Fingerprint

Erythema Multiforme
Bipolar Disorder
Drug Hypersensitivity Syndrome
Off-Label Use
Skin
Major Depressive Disorder
Exanthema
Antidepressive Agents
Therapeutics
cyclobenzaprine
lamotrigine

Keywords

  • Cyclobenzaprine
  • Erythema multiforme
  • Lamotrigine
  • Mood disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Erythema multiforme vs. dress syndrome associated with the combined use of lamotrigine and cyclobenzaprine : A case report. / Bicknell, Lindsay T Morgan; Sanches, Marsal; Schatte, Dawnelle.

In: International Journal of Psychiatry in Medicine, Vol. 44, No. 4, 2012, p. 305-314.

Research output: Contribution to journalArticle

@article{5e343ad1312f4fe7a1d4445ee5d5bbb8,
title = "Erythema multiforme vs. dress syndrome associated with the combined use of lamotrigine and cyclobenzaprine: A case report",
abstract = "Lamotrigine is FDA-approved as a maintenance treatment of bipolar disorder, but its common off-label uses include bipolar depression and antidepressant augmentation in patients with major depressive disorder. Among other adverse effects, cutaneous reactions, particularly erythema multiforme, are cited as concerns during treatment with this medication. In order to minimize the risk of cutaneous side effect, efforts have been made to identify factors associated with a higher rate of lamotrigine-induced rash. We report here a case of Drug Reaction with Eosinophilia and Systemic Symptoms apparently precipitated by the associated use of lamotrigine and cyclobenzaprine.",
keywords = "Cyclobenzaprine, Erythema multiforme, Lamotrigine, Mood disorders",
author = "Bicknell, {Lindsay T Morgan} and Marsal Sanches and Dawnelle Schatte",
year = "2012",
doi = "10.2190/PM.44.4.b",
language = "English (US)",
volume = "44",
pages = "305--314",
journal = "International Journal of Psychiatry in Medicine",
issn = "0091-2174",
publisher = "Baywood Publishing Co. Inc.",
number = "4",

}

TY - JOUR

T1 - Erythema multiforme vs. dress syndrome associated with the combined use of lamotrigine and cyclobenzaprine

T2 - A case report

AU - Bicknell, Lindsay T Morgan

AU - Sanches, Marsal

AU - Schatte, Dawnelle

PY - 2012

Y1 - 2012

N2 - Lamotrigine is FDA-approved as a maintenance treatment of bipolar disorder, but its common off-label uses include bipolar depression and antidepressant augmentation in patients with major depressive disorder. Among other adverse effects, cutaneous reactions, particularly erythema multiforme, are cited as concerns during treatment with this medication. In order to minimize the risk of cutaneous side effect, efforts have been made to identify factors associated with a higher rate of lamotrigine-induced rash. We report here a case of Drug Reaction with Eosinophilia and Systemic Symptoms apparently precipitated by the associated use of lamotrigine and cyclobenzaprine.

AB - Lamotrigine is FDA-approved as a maintenance treatment of bipolar disorder, but its common off-label uses include bipolar depression and antidepressant augmentation in patients with major depressive disorder. Among other adverse effects, cutaneous reactions, particularly erythema multiforme, are cited as concerns during treatment with this medication. In order to minimize the risk of cutaneous side effect, efforts have been made to identify factors associated with a higher rate of lamotrigine-induced rash. We report here a case of Drug Reaction with Eosinophilia and Systemic Symptoms apparently precipitated by the associated use of lamotrigine and cyclobenzaprine.

KW - Cyclobenzaprine

KW - Erythema multiforme

KW - Lamotrigine

KW - Mood disorders

UR - http://www.scopus.com/inward/record.url?scp=84881655268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881655268&partnerID=8YFLogxK

U2 - 10.2190/PM.44.4.b

DO - 10.2190/PM.44.4.b

M3 - Article

C2 - 23885514

AN - SCOPUS:84881655268

VL - 44

SP - 305

EP - 314

JO - International Journal of Psychiatry in Medicine

JF - International Journal of Psychiatry in Medicine

SN - 0091-2174

IS - 4

ER -